# Study in End Stage Renal Disease (ESRD) Patients on Hemodialysis to Determine Non-inferiority of the Theranova Dialyzer Compared to the FX80 Dialyzer

Study · id `cardio:ct-nct03547323` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03547323](<https://clinicaltrials.gov/study/NCT03547323>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03547323

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.

## Technical summary

Registry record NCT03547323. Randomized; no masking; primary purpose treatment. Start 2018-09-14 (actual); primary completion 2019-06-14 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 156 participants (enrolled count; ClinicalTrials.gov record NCT03547323, source copy `cardio:ctgov-nct03547323-2025-03-13`, retrieved 2026-10-26)
- Started: 2018-09-14 (actual) (ClinicalTrials.gov record NCT03547323, source copy `cardio:ctgov-nct03547323-2025-03-13`, retrieved 2026-10-26)
- Primary completion: 2019-06-14 (actual) (ClinicalTrials.gov record NCT03547323, source copy `cardio:ctgov-nct03547323-2025-03-13`, retrieved 2026-10-26)
- Completion: 2019-06-14 (actual) (ClinicalTrials.gov record NCT03547323, source copy `cardio:ctgov-nct03547323-2025-03-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03547323, source copy `cardio:ctgov-nct03547323-2025-03-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03547323-2025-03-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study in End Stage Renal Disease (ESRD) Patients on Hemodialysis to Determine Non-inferiority of the Theranova Dialyzer Compared to the FX80 Dialyzer
- Condition: End Stage Renal Disease
- Intervention (Device): Theranova 400 Dialyzer
- Intervention (Device): FX80 Dialyzer
- Lead sponsor: Vantive Health LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Baxter Healthcare Corporation
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Vantive Health LLC (`cardio:org-vantive-health-llc`)
- Registry lists this organization as a collaborator: Baxter Healthcare Corporation (`cardio:org-baxter-healthcare-corporation`)

## Provenance

Content hash: ebe791410b7153ed248fcefe09d5f89317e2900d2437699ca6b9aa30b7804677
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
